Frontiers in Microbiology (May 2022)

In vitro and in vivo Activity of Phibilin Against Candida albicans

  • Zhongjie Li,
  • Xiaoyuan Jing,
  • Yaping Yuan,
  • Yingbin Shui,
  • Shasha Li,
  • Zhuoran Zhao,
  • Bo Deng,
  • Wenlu Zhang

DOI
https://doi.org/10.3389/fmicb.2022.862834
Journal volume & issue
Vol. 13

Abstract

Read online

The increase in the occurrence of antifungal-resistant Candida albicans infections necessitates more research to explore alternative effective and safe agents against this fungus. In this work, Phibilin, a new antimicrobial peptide obtained from Philomycus bilineatus and used in traditional Chinese medicine, effectively inhibits the growth and activities of C. albicans, including the clinical resistant strains. Phibilin is a fungicidal antimicrobial peptide that exhibited its antimicrobial effect against C. albicans mainly by disrupting the membrane and interacting with the DNA of the fungi. In particular, Phibilin induces the necrosis of C. albicans via the ROS-related pathway. Moreover, this antifungal compound inhibited the biofilm formation of C. albicans by preventing the development of hyphae in a dose-dependent manner. Furthermore, Phibilin and clotrimazole displayed a synergistic effect in inhibiting the growth of the fungi. In the mouse cutaneous infection model, Phibilin significantly inhibited the formation of skin abscesses and decreased the counts of C. albicans cells in the infected area. Overall, Phibilin is potentially an effective agent against skin infections caused by C. albicans.

Keywords